Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Past, Current, and Future of Immunotherapies for Prostate Cancer.

Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD.

Front Oncol. 2019 Sep 11;9:884. doi: 10.3389/fonc.2019.00884. eCollection 2019. Review.

2.

Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.

Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.

Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19. Review.

PMID:
29056275
3.

Effective combinatorial immunotherapy for castration-resistant prostate cancer.

Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA.

Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Erratum in: Nature. 2017 May 3;545(7652):116.

4.

Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.

Prokhnevska N, Emerson DA, Kissick HT, Redmond WL.

Adv Exp Med Biol. 2019;1210:121-147. doi: 10.1007/978-3-030-32656-2_7.

PMID:
31900908
5.

A comprehensive review of immunotherapies in prostate cancer.

Maia MC, Hansen AR.

Crit Rev Oncol Hematol. 2017 May;113:292-303. doi: 10.1016/j.critrevonc.2017.02.026. Epub 2017 Mar 2. Review.

PMID:
28427519
6.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
7.

Oncolytic adenovirus-mediated therapy for prostate cancer.

Sweeney K, Halldén G.

Oncolytic Virother. 2016 Jul 14;5:45-57. doi: 10.2147/OV.S63047. eCollection 2016. Review.

8.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
9.

Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.

Mehta AR, Armstrong AJ.

Ther Adv Urol. 2016 Feb;8(1):9-18. doi: 10.1177/1756287215603558. Review.

10.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
11.

Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.

Gomella LG, Gelpi-Hammerschmidt F, Kundavram C.

Can J Urol. 2014 Apr;21(2 Supp 1):48-56. Review.

12.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

13.

Cellular immunotherapies for prostate cancer.

McNeel DG.

Biomed Pharmacother. 2007 Jul;61(6):315-22. Epub 2007 Jan 26. Review.

PMID:
17306498
14.
15.

Immunotherapy for prostate cancer: recent developments and future challenges.

Schweizer MT, Drake CG.

Cancer Metastasis Rev. 2014 Sep;33(2-3):641-55. doi: 10.1007/s10555-013-9479-8. Review.

16.

Combining immunotherapies for the treatment of prostate cancer.

Redman JM, Gulley JL, Madan RA.

Urol Oncol. 2017 Dec;35(12):694-700. doi: 10.1016/j.urolonc.2017.09.024. Review.

17.

Clinical development of immunotherapy for prostate cancer.

Noguchi M, Koga N, Igawa T, Itoh K.

Int J Urol. 2017 Sep;24(9):675-680. doi: 10.1111/iju.13397. Epub 2017 Jun 21. Review.

18.

Advancing therapies in metastatic castration-resistant prostate cancer.

Baciarello G, Gizzi M, Fizazi K.

Expert Opin Pharmacother. 2018 Nov;19(16):1797-1804. doi: 10.1080/14656566.2018.1527312. Epub 2018 Oct 12. Review.

PMID:
30311804
19.

Potentiating prostate cancer immunotherapy with oncolytic viruses.

Lee P, Gujar S.

Nat Rev Urol. 2018 Apr;15(4):235-250. doi: 10.1038/nrurol.2018.10. Epub 2018 Feb 13. Review.

PMID:
29434366
20.

A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.

Martin GA, Chen AH, Parikh K.

Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027. Review.

PMID:
28895177

Supplemental Content

Support Center